XELLSMART
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

XELLSMART Trademark

Serial Number: 79387594

XELLSMART is a trademark filed by XellSmart Biomedical (Suzhou) Co. Ltd. on November 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

XellSmart Biomedical (Suzhou) Co. Ltd. (3 trademarks)

Unit 201, Building 3, Zone B,

Entity Type: 99

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (3 trademarks)

Unit 201, Building 3, Zone B

Entity Type: 98

Trademark Details

Filing Date

November 2, 2023

Registration Date

Not Registered

Goods & Services

Product quality testing; chemical research; bacteriological research; biological research; Medical and Scientific research, namely, conducting clinical trials for others; medical research; biological cloning services; stem cell research services; medical research laboratory services; genetic testing for scientific research purposes

Medical clinic services; telemedicine services; therapy services, namely, cognitive therapy services, voice and speech therapy services, insomnia therapy services, physiotherapy, psychological counseling services, psychotherapy services, respiratory therapy services, drug rehabilitation counseling services, addiction treatment services; stem cell therapy services; health counselling; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; convalescent home services; advisory services relating to health; services of a psychologist; massage; rental of sanitary installations

Medicines for human purposes, namely, medicines for the treatment of degenerative disease, motor neuron disease; medicines for human purposes, namely, medicines for the treatment of epilepsy; medicines for human purposes, namely, medicines for the treatment of macular degeneration; medicines for human purposes, namely, medicines for alleviating constipation; medicines for human purposes, namely, medicines for the treatment of cardiovascular disease, coronary heart disease, angina pectoris, myocarditis, cardiac arrhythmia, tumors, infectious diseases, autoimmune disease, blood disease, mental illness, ophthalmic disorders, metabolic diseases and disorders in the nature of diabetes, kidney diseases, osteoporosis; antiviral medicines; anesthetics; antibiotics and bacterial poisons; medicines for human purposes, namely, biological products, prepared by using biological materials in the nature of microorganisms, cells, and various animal and human tissues and liquids, obtained by biological techniques, namely, genetic engineering, cell engineering, protein engineering, fermentation engineering for the treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, infectious diseases, autoimmune diseases, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; medicines for human purposes, namely, parenteral nutrition supplements; Transplants, namely, bone graft materials derived from human tissue, processed human donor skin for the replacement of soft tissue, surgical mesh comprised primarily of living tissue, ex vivo cells, namely, immune cells, red blood cells, t cells, nk cells, islet cells; collagen for medical purposes; immunostimulants; nutraceutical preparations for therapeutic or medical purposes for use in the treatment of degenerative diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and arthritis; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparation for treating microbial diseases, namely, antibiotics; pharmaceutical preparations for the treatment of mental illness and ophthalmic disease; pharmaceutical preparations for contrast agent, infectious disease, blood disease and kidney disease; pharmaceutical preparations containing chemical drugs and biological products for the prevention and treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune diseases; pharmaceutical preparations containing chemical drugs and biological products for antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes and parenteral nutrition purposes; chemico-pharmaceutical preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases and infectious diseases; chemico-pharmaceutical preparations for relief from asthma and coughs; chemico-pharmaceutical preparations for parenteral nutrition purposes, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; pharmaceutical preparations for use in tissue and organ transplantation, pharmaceutical preparations for human use for the prevention of solid organ transplant rejection, pharmaceutical preparations for transplantation and transplant-related conditions affecting the kidney, bone graft materials derived from human tissue, processed human donor skin for the replacement of soft tissue, surgical mesh comprised primarily of living tissue, ex vivo cells, namely, immune cells, red blood cells, t cells, nk cells, islet cells; vaccines; drugs for medical purposes for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune disease; drugs for medical purposes for relief from asthma and coughs; drugs for medical purposes, namely, parenteral nutrition purposes, antipyretic and analgesic purposes, nonsteroidal anti-inflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; serums for medical purposes for the treatment of skin; opotherapy preparations; blood plasma; biological preparations for medical purposes, namely, antitoxic sera, antitoxins, toxoids, toxins, human and veterinary vaccines ?and for use in cell cultures; biological preparations for veterinary purposes, namely, veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle, veterinary pharmaceutical preparations for the treatment of arthritis, muscle soreness and sprains, veterinary pharmaceutical preparations for the treatment of bacterial infections in dogs, veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, topical infections; veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia; veterinary pharmaceutical preparations for the treatment of vitamin deficiencies; veterinary preparations for treatment of intestinal bacteria; biochemical preparations for veterinary purposes for the treatment of tumors; enzymes for medical purposes; enzyme preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for veterinary purposes, namely, laxatives for veterinary purposes, pain relief medication for veterinary purposes, suppositories for veterinary purposes; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 11, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 11, 2025 RCSC
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 18, 2025 ADCH
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 5, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 17, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 17, 2025 OPNR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 7, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 7, 2025 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 6, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 6, 2024 GNSL
SUSPENSION LETTER WRITTEN
Nov 6, 2024 CNSL
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 18, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 18, 2024 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 17, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 17, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 17, 2024 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 15, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 15, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 15, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 4, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 16, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 15, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 25, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 24, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 13, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 23, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 18, 2024 REPR